Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study

Doecke, J. D., Hartnell, F., Bampton, P., Bell, S., Mahy, G., Grover, Z., Lewindon, P., Jones, L. V., Sewell, K., Krishnaprasad, K., Prosser, R., Marr, D., Fischer, J., Thomas, G. R., Tehan, J. V., Ding, N. S., Cooke, S. E., Moss, K., Sechi, A., De Cruz, P., Grafton, R., Connor, S. J., Lawrance, I. C., Gearry, R. B., Andrews, J. M. and Radford-Smith, G. L. (2017) Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study. Alimentary Pharmacology and Therapeutics, 45 4: 542-552. doi:10.1111/apt.13880


Author Doecke, J. D.
Hartnell, F.
Bampton, P.
Bell, S.
Mahy, G.
Grover, Z.
Lewindon, P.
Jones, L. V.
Sewell, K.
Krishnaprasad, K.
Prosser, R.
Marr, D.
Fischer, J.
Thomas, G. R.
Tehan, J. V.
Ding, N. S.
Cooke, S. E.
Moss, K.
Sechi, A.
De Cruz, P.
Grafton, R.
Connor, S. J.
Lawrance, I. C.
Gearry, R. B.
Andrews, J. M.
Radford-Smith, G. L.
Title Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study
Journal name Alimentary Pharmacology and Therapeutics   Check publisher's open access policy
ISSN 1365-2036
0269-2813
Publication date 2017-02-01
Year available 2016
Sub-type Article (original research)
DOI 10.1111/apt.13880
Open Access Status Not yet assessed
Volume 45
Issue 4
Start page 542
End page 552
Total pages 11
Place of publication Chichester, West Sussex, United Kingdom
Publisher Wiley-Blackwell Publishing
Collection year 2018
Language eng
Formatted abstract
Background: Maintenance anti-tumour necrosis factor-α (anti-TNFα) treatment for Crohn's disease is the standard of care for patients with an inadequate response to corticosteroids and immunomodulators.

Aim: To compare the efficacy and safety of infliximab and adalimumab in clinical practice and assess the value of concomitant immunomodulator therapy.

Methods: We performed an observational cohort study in consecutive patients with Crohn's disease qualifying for anti-TNFα treatment in Australia and New Zealand between 2007 and 2011. Demographic and clinical data were prospectively recorded to identify independent factors associated with induction and maintenance of response to infliximab or adalimumab, or to either anti-TNFα therapy.

Results: Three hundred and twenty-seven patients (183 infliximab, 144 adalimumab) successfully applied for treatment. Eighty-nine percent responded in all groups and median maintenance of response was similar for the two agents. Concomitant immunomodulator with infliximab, but not adalimumab, demonstrated a significantly longer response overall (P = 0.002), and significantly fewer disease and treatment-related complications (P = 0.017). Corticosteroids at baseline, and/or in the preceding 12 months, were associated with a 9–13 times greater risk of disease flare during maintenance treatment as compared to no corticosteroids (P < 0.0001). Maintenance of response was similar in the anti-TNF naïve and anti-TNF experienced subgroups.

Conclusions: In this large, real-life study, we demonstrate infliximab and adalimumab to have similar response characteristics. However, infliximab requires concomitant immunomodulator to achieve optimal maintenance of response comparable to adalimumab monotherapy. The results of this study will assist clinicians in further optimising patient care in their day-to-day clinical practice.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: HERDC Pre-Audit
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 2 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 2 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 26 Mar 2017, 01:00:51 EST by Web Cron on behalf of Learning and Research Services (UQ Library)